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Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the
anterior cingulate cortex in psychotic and nonpsychotic depression,
bipolar disorder and schizophrenia: implications for novel mGluR-based
therapeutics
Abstract

Background: Metabotropic glutamate receptors 2/3 (mGluR2/3) and 5 (mGluR5) are novel therapeutic
targets for major depression (MD), bipolar disorder (BD) and schizophrenia. We aimed to determine
whether mGluR2/3 and mGluR5 binding in the anterior cingulate cortex (ACC), a brain region essential for
the regulation of mood, cognition and emotion, were differentially altered in these pathologies. Methods:
Using postmortem human brains derived from 2 cohorts, [3H]LY341495 binding to mGluR2/3 and
[3H]MPEP binding to mGluR5 were measured by receptor autoradiography in the ACC. The first cohort
comprised samples from individuals who had MD with psychosis (MDP), MD without psychosis (MDNP)
and matched controls (n = 11-12 per group). The second cohort comprised samples from individuals who had
MDNP, BD, schizophrenia and matched controls (n = 15 per group). Results: No differences in mGluR2/3 or
mGluR5 binding were observed in the MDP, MDNP, BD or schizophrenia groups compared with the control
group (all p > 0.05). Importantly, there were also no differences in binding densities between the psychiatric
disorders (p > 0.05). We did, however, observe age-related effects, with consistent negative associations
between mGluR2/3 and age in the control group (r < -0.575, p < 0.025) and the psychotic disorder groups
(MDP and schizophrenia: r = -0.765 to -0.515, p < 0.05), but not in the mood disorder groups (MDNP, BD).
Limitations: Replication in larger independent cohorts and medication-naive individuals would strengthen
these findings. Conclusion: Our findings suggest that mGluRs are unaltered in the ACC; however, the
presence of altered receptor function cannot be discounted and requires further investigation. Taken together
with previous studies, which report differential changes in mGluR2, 3 and 5 across these disorders, we suggest
mGluRs may be affected in a brain region-specific manner.
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Metabotropic glutamate receptor mGluR2/3 and
mGluR5 binding in the anterior cingulate cortex in
psychotic and nonpsychotic depression, bipolar
disorder and schizophrenia: implications for novel
mGluR-based therapeutics
Natalie Matosin, BMSc Hons; Francesca Fernandez-Enright, PhD; Elisabeth Frank, PhD;
Chao Deng, PhD; Jenny Wong, PhD; Xu-Feng Huang, MD, PhD; Kelly A. Newell, PhD
Matosin, Fernandez-Enright, Frank, Deng, Wong, Huang, Newell — Faculty of Science, Medicine and Health, University of
Wollongong, New South Wales; Matosin, Fernandez-Enright, Frank, Deng, Wong, Huang, Newell — Illawarra Health and Medical Research Institute, Wollongong, New South Wales; Matosin, Fernandez-Enright, Frank, Deng, Huang, Newell — Schizophrenia Research Institute, Sydney, New South Wales; Fernandez-Enright — School of Psychology, Faculty of Social Science, University of Wollongong, New South Wales, Australia

Background: Metabotropic glutamate receptors 2/3 (mGluR2/3) and 5 (mGluR5) are novel therapeutic targets for major depression
(MD), bipolar disorder (BD) and schizophrenia. We aimed to determine whether mGluR2/3 and mGluR5 binding in the anterior cingulate
cortex (ACC), a brain region essential for the regulation of mood, cognition and emotion, were differentially altered in these pathologies.
Methods: Using postmortem human brains derived from 2 cohorts, [3H]LY341495 binding to mGluR2/3 and [3H]MPEP binding to
mGluR5 were measured by receptor autoradiography in the ACC. The first cohort comprised samples from individuals who had MD with
psychosis (MDP), MD without psychosis (MDNP) and matched controls (n = 11–12 per group). The second cohort comprised samples
from individuals who had MDNP, BD, schizophrenia and matched controls (n = 15 per group). Results: No differences in mGluR2/3 or
mGluR5 binding were observed in the MDP, MDNP, BD or schizophrenia groups compared with the control group (all p > 0.05). Importantly, there were also no differences in binding densities between the psychiatric disorders (p > 0.05). We did, however, observe age-
related effects, with consistent negative associations between mGluR2/3 and age in the control group (r < –0.575, p < 0.025) and the
psychotic disorder groups (MDP and schizophrenia: r = –0.765 to –0.515, p < 0.05), but not in the mood disorder groups (MDNP, BD).
Limitations: Replication in larger independent cohorts and medication-naive individuals would strengthen these findings. Conclusion:
Our findings suggest that mGluRs are unaltered in the ACC; however, the presence of altered receptor function cannot be discounted
and requires further investigation. Taken together with previous studies, which report differential changes in mGluR2, 3 and 5 across
these disorders, we suggest mGluRs may be affected in a brain region–specific manner.

Introduction
Major depression (MD) is an important cause of disability as
well as financial and emotional burden worldwide. While traditionally the monoaminergic system has been implicated in the
pathophysiology and treatment of MD, evidence from clinical,

preclinical and postmortem studies are rapidly implicating glutamatergic dysregulation in MD.1 Accordingly, metabotropic
glutamate receptors (mGluRs), which slowly mediate glutamatergic neurotransmission, are promising therapeutic targets for
the treatment of MD. The challenges, however, in elucidating
the pathophysiology of MD, and therefore appropriate
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treatment strategies, are the heterogeneity of the disorder
and its association with other psychiatric and mood disorders, such as bipolar disorder (BD) and schizophrenia.
Major depression with psychotic features (psychotic depression) is classified as a subtype of major depression in DSM-IV.
As recently discussed by Rothschild,2 psychotic depression is
associated with BD. Studies have shown that patients with
psychotic depression had an increased risk for BD compared
with patients with nonpsychotic depression. In contrast, evidence suggests psychotic depression is distinct from schizophrenia.2 It is necessary to characterize the pathophysiology of
depression, including its psychotic and nonpsychotic types,
and determine the differences and similarities between BD and
schizophrenia, as this has crucial implications for advising the
use of certain pharmacotherapeutics.
Several lines of evidence suggest the involvement of the
anterior cingulate cortex (ACC) in the pathophysiology of
depression. It has critical control over mood, emotion and
cognition, as proven by bilateral cingulotomy psychosurgery, which can relieve depression and some psychiatric
symptoms.3 Concurrently, reduced glutamate levels have
been reported in the ACC of patients with depression,4–6
and this is reflected at the protein level for various markers
expressed at the glutamatergic synapse.7–9 The involvement
of glutamatergic dysfunction in depression may be specific
to this brain region, as 1 group found alterations of various
postsynaptic glutamatergic proteins (NR1 subunit of the Nmethyl-d-aspartate receptor [NMDAR], postsynaptic density protein 95 [PSD95] and postsynaptic density protein 93
[PSD93]) in the ACC, but not in the dorsolateral prefrontal
cortex (DLPFC), in individuals with depression.7
Metabotropic glutamate receptors, particularly
mGluR2/3 and mGluR5, have been identified as novel
therapeutic targets for mood and psychiatric disorders because of their ability to modulate glutamatergic neurotransmission.10–12 Whereas mGluR2/3 are predominately presynaptic receptors that inhibit glutamate and γ-aminobutyric
acid (GABA) release into the synapse,13 mGluR5 are primarily expressed postsynaptically, where they modulate the
glutamate response, especially in association with the
N MDAR. 11 In addition to their therapeutic potential,
mGluRs are also implicated in the pathophysiology of these
disorders. For example, numerous animal studies demonstrate that selected mGluRs are affected in animal models of
depression,14,15 and knockout animals display psychotic
phenotypic behaviours.11,13 From these studies, it is becoming increasingly clear that there may be opposing actions of
the glutamatergic system in these disorders, particularly as
mGluR2/3 and mGluR5 blockade appear to be beneficial
for the treatment of depression, while potentiation of these
receptors has preclinical efficacy for the treatment of psych
osis.1,11,13 Hence, mGluR2/3 and mGluR5 may be differentially involved in the pathophysiology of mood and psychotic disorders.
We sought to determine whether mGluR2/3 and mGluR5
were altered in the ACC of individuals with MD (in the presence and absence of psychosis) and the associated pathologies BD and schizophrenia. We studied 2 independent post-
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mortem cohorts from the Stanley Medical Research Institute:
the Stanley Depression Collection, consisting of samples from
individuals who had MD without psychosis (MDNP), MD
with psychosis (MDP) and controls, and the Stanley Neuropathology Consortium, consisting of samples from individ
uals who had diagnoses of MDNP, BD and schizophrenia
and controls. We measured mGluR2/3 and mGluR5 binding
in the ACC (Brodmann area [BA] 24) of these samples by in
situ receptor autoradiography. As the ACC is implicated in
the emotional and cognitive deficits associated with these
disorders, the findings from this study have translational implications for novel drugs aimed to treat mood and cognitive
deficits in patients with these disorders.

Methods
Human postmortem brain samples
Frozen postmortem brain tissue was acquired through the
Stanley Medical Research Institute. From the Depression Collection, we obtained samples from 24 individuals who had
MD (MDNP: n = 12; MDP: n = 11) and controls (n = 12)
matched according to age, postmortem interval (PMI), re
frigeration interval and brain pH (Table 1). Psychosis could not
be confirmed in 1 of the MD samples, who was therefore excluded from psychosis-specific analyses. From the Neuro
pathology Consortium, we obtained samples from 60 individuals who had MDNP, BD and schizophrenia and controls (n =
15 per group), matched for age, sex, race and PMI (Table 2).
Detailed clinical and demographic information regarding
these cohorts have been published previously.16,17 The work
described in this study was approved by the Human Research
Ethics Committee at the University of Wollongong and conducted according to their guidelines (HE13/069).

Receptor autoradiography
Frozen coronal sections at the level of the ACC (BA24; 14 µm)
were mounted onto slides and stored at –80°C until the day
of the assay. Receptor autoradiography studies were based
on protocols described previously (mGluR2/3; 18,19
mGluR520,21). Autoradiography exposures were optimized for
mGluR2/3 and mGluR5 to ensure that each cortical layer
could be quantified on a linear scale and none of the cortical
layers with high expression were overexposed. The signal to
noise ratio of mGluR2/3 and mGluR5 binding in all groups
assayed were well above the nonspecific control. Two sections for each individual were analyzed for total binding, and
adjacent sections were used to determine nonspecific binding. All experiments were performed blind to diagnoses.
mGluR2/3
Tissue sections were preincubated in a buffer solution containing 50 mM Tris buffer, 2 mM MgCl2 and 2 mM CaCl2 (pH 7) at
room temperature for 2 × 10 minutes. Subsequently, slides
were incubated for 60 minutes at room temperature in buffer
solution containing 50 nM [3H]LY341495 (specific mGluR2/3
agonist; specific activity 40 Ci/mmol; American Radiolabelled
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Imaging and quantification

Chemicals). To determine nonspecific binding, adjacent sections were additionally incubated with 50 nM [3H]LY341495
and 0.01 mM DCG-IV (specific mGluR2/3 agonist; Sigma). After incubation, the slides were washed in 4°C washing buffer
(50 mM Tris buffer, pH 7) for 2 × 30 seconds and 1 × 1 minute.
This protocol favours mGluR2 over mGluR3 binding.19

Together with [3H] microscale autoradiographic standards
(Amersham Biosciences), sections were exposed to tritium
sensitive Kodak Biomax MR film (Kodak) for 10 weeks. Films
were developed using the AGFA CP1000 film developer
(Agfa-Gavaert N.V.), scanned using a GS800 densitometer
(BioRad) and analyzed using Multi-Analyst software (BioRad). Quantification was performed blind to diagnoses.
Radioligand binding signals were expressed in counts per
minute (cpm)/mm2 and, with the use of standards and the
specific activities of the respective radioligands, were converted to fmol/mg tissue equivalents.

mGluR5
Tissue sections were preincubated for 15 minutes at room
temperature in 50 mM TrisNaCl (pH 7.5). Slides were then
incubated in solution containing 10 nM [3H]MPEP (specific
mGluR5 antagonist; specific activity 60 Ci/mmol; American
Radiolabelled Chemicals) and 50 mM TrisNaCl for 90 minutes at room temperature. Adjacent sections were incubated
in the same solution with the addition of 10 µM unlabelled
MPEP (Sigma) to determine nonspecific binding. Slides were
washed in 4°C TrisNaCl (pH 7.5) for 2 × 3 minutes and
briefly dipped in 4°C MilliQ-water.

Statistical analysis
As data were normally distributed across both cohorts, we used
parametric tests. No data points were identified as outliers (± 2

Table 1: Cohort demographic and clinical descriptives of tissue sample donors within the Depression Collection
Group; mean (range)*
Descriptive
No. of patient donors

Control

MD (total)

MDP

MDNP

12

24

11

12

46.8 (24–62)

42.2 (24–63)

39.6 (28–63)

42.8 (24–56)

Illness duration, yr

—

11.7 (0.1–31)

11 (3–21)

12.3 (0.1–31)

Age at illness onset, yr

—

29.7 (13–45)

28.6 (13–39)

30.5 (14–45)

Sex, male:female

8:4

13:11

5:6

7:5

25.3 (9–65)

29.6 (13–65)

33.1 (19–52)

23.6 (13–38)

Age at death, yr

PMI, h
Refrigeration, h†
pH
Hemisphere, right:left

7.42 (3–18)

7.96 (1–31)

7.18 (1–14)

8 (2–31)

6.64 (6.31–6.57)

6.6 (6.3–6.9)

6.6 (6.3–6.74)

6.7 (6.52–6.9)
7:5

6:6

15:9

8:3

Antipsychotics‡

0

12

9

3

Fluphenazine equivalents

—

2 242 (100–6 500)

2 533 (100–6 500)

1 367 (100–3 000)

MD = major depression; MDNP = major depression without psychosis; MDP = major depression with psychosis; PMI = postmortem interval.
*Unless otherwise indicated.
†Values refer to the mean interval between patient death and refrigeration of the body at the medical examiner’s office.
‡Number of patients with a prescription for antipsychotics at the time of death.

Table 2: Cohort demographic and clinical descriptives of tissue sample donors within the Neuropathology
Consortium
Group; mean (range)*
Descriptive
No. of patient donors
Age at death, yr

Control

MD

Bipolar disorder

Schizophrenia

15

15

15

15

48.1 (29–68)

46.5 (30–65)

42.3 (25–61)

44.2 (25–62)

Illness duration, yr

—

12.6 (1–42)

20.13 (6–43)

21.3 (5–45)

Age at illness onset, yr

—

33.9 (11–54)

21.5 (7–39)

23.2 (13–42)

Sex, male:female

9:6

9:6

9:6

9:6

PMI, h

23.7 (8–42)

27.5 (7–47)

32.5 (13–62)

33.7 (12–61)

FST, d

338.27 (31–774)

434 (86–931)

620 (224–836)

621.13 (68–938)

6.3 (5.8–6.6)

6.2 (5.6–6.5)

6.2 (5.8–6.5)

6.1 (5.8–6.6)

7:8

6:9

8:7

6:9

Antipsychotics†

0

0

12

14

Fluphenazine equivalents

—

—

26 033 (200–60 000)

56 000 (1 000–2 000)

pH
Hemisphere, right:left

FST = freezer storage time; MD = major depression; PMI = postmortem interval.
*Unless otherwise indicated.
†Number of patients with a prescription for antipsychotics at the time of death.
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standard deviations). The depression collection and the neuropathology consortium were analyzed separately. We used an
alysis of variance (ANOVA) followed by a Tukey post hoc test
to compare differences in mGluR2/3 and mGluR5 binding between the diagnoses in the 2 cohorts (i.e., MDNP, MDP v. control and MDNP, BD, schizophrenia and control). Subsequently,
we completed Pearson correlations to determine any influence
of continuous variables on the data. We then carried out analyses of covariance (ANCOVAs) in which we compared binding
values between the diagnostic groups in the 2 cohorts, controlling for variables that significantly correlated with the data. Statistical analyses were performed using SPSS software version
19.0. We considered results to be significant at p < 0.05, and data
are presented as means ± standard errors of the mean (SEM).

markers (various measures of NMDAR, 2-amino-3-(3-hydroxy5-methylisoxazol-4-yl propionate receptor [AMPAR] and kainate
receptors) and signalling partners (PSD95, brain-derived neurotrophic factor [BDNF] and protein kinase C [PKC]) that have previously been measured in the cingulate cortex (BA not specified)
was performed using the SNCID as previously described.22 We
used a nonparametric method (Spearman correlation) to minimize effects caused by differences in units and/or distribution
patterns.23 All 60 individuals were included, and significance
was set at p < 0.05. Detailed information regarding the measurement and experimental protocol for each marker is available on
the SNCID database (http://sncid.stanleyresearch.org).

The Stanley Neuropathology Consortium Integrative Database

Distribution

The Stanley Neuropathology Consortium Integrative Database
(SNCID; http://sncid.stanleyresearch.org)22 includes 1762 pathological markers measured in 12 different brain regions by the
Neuropathology Consortium. In line with the hypotheses of the
present study, we sought to determine if there were associations
between our measures of mGluR2/3 and mGluR5 and measures
of other glutamate-related proteins, specifically within the cingulate cortex. Exploratory correlation analyses of glutamatergic

We found that mGluR2/3 ([3H]LY341495) and mGluR5 ([3H]
MPEP) binding were highly expressed in the cortical areas of
brain slices across the 2 cohorts (Fig. 1). Whereas mGluR5
binding was homogeneously distributed across all cortical
layers, mGluR2/3 binding showed pronounced layer differences; the superficial one-third of the cortex had significantly
higher binding than the lower layers (p < 0.001) and was analyzed accordingly.

A

Results

Control

Major depression
(with psychosis)

Major depression
(without psychosis)

Control

Major depression

Bipolar disorder

Nonspecific

mGluR2/3

mGluR5

B

Schizophrenia

Nonspecific

mGluR2/3

mGluR5

Fig. 1: Representative receptor autoradiographs of mGluR2/3 [3H]LY341495 and mGluR5 [3H]MPEP binding from the anterior cingulate cortex
of samples from the (A) Stanley Depression Collection (control, major depression with psychosis, major depression without psychosis) and the
(B) Stanley Neuropathology Consortium (control, major depression, bipolar disorder and schizophrenia). A representative nonspecific binding
has been included for each cohort. mGluR2/3 [3H]LY341495 and mGluR5 [3H]MPEP binding densities were not different between pathological
and control groups.
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Depression Collection

Effects of demographic and clinical variables
Pearson correlations for continuous variables (pH, age at
death, PMI, refrigeration interval, brain weight, age at disease onset, duration of illness and lifetime fluphenazine
equivalents) are presented in Table 3 and in the Appendix,
Table S1, available at jpn.ca. Age at death was consistently
associated with mGluR2/3 binding in the control group
(total: r = –0.551, p = 0.06; upper: r = –0.747, p = 0.005; lower:
r = –0.134; p = 0.94) and in the MDP group (total: r = –0.765,
p = 0.006; upper: r = –0.748, p = 0.008; lower: r = –0.692, p =
0.018) but not in the MDNP group (total: r = –0.371, p =
–0.24; upper: r = –0.383, p = 0.22; lower: r = –0.335, p = 0.29).
Age at death correlated positively with mGluR5 in the
MDNP group (r = 0.587, p = 0.045) but not in the MDP
group (r = 0.551, p = 0.08) or the control group (r = 0.023, p =
0.94; Table 3).
Overall, there was no effect of lifetime antipsychotic exposure on total or lower mGluR2/3 (total: r = –0.289, p =
0.19; lower: r = –0.047, p = 0.84) or mGluR5 (r = 0.005, p =
0.98) in all individuals who had MD (MDNP and MDP), but
we observed a negative association with mGluR2/3, specif
ically in the upper layer (r = –0.460, p = 0.031). Power for the
subgroups was notably low (MDNP: n = 3; MDP: n = 9) and
was therefore not reported (Table 3).

Normalized mGluR2/3 binding density, fmol/mg

Diagnosis-related effects
One-way ANOVA revealed no significant diagnostic alterations in mGluR2/3 (total: F2,32 = 0.306, p = 0.74; upper: F2,32 =
1.502, p = 0.24; lower: F2,32 = 0.338, p = 0.72) or mGluR5 (F2,32 =
0.074, p = 0.93) comparing the MDP, MDNP and control
groups (Fig. 2). Subsequently, we performed ANCOVAs to
control for age at death, brain pH, refrigeration interval,
brain weight and PMI; however, significance was unchanged for mGluR2/3 (total: F2,27 = 0.934, p = 0.43; upper:
F2,27 = 0.761, p = 0.72; lower: F2,27 = 0.025, p = 0.98) or mGluR5
(F2,27 = 1.010, p = 0.46). In addition, we performed an in
dependent t test to compare all individuals with depression
(n = 24) and controls (n = 12). No significance was seen for
either mGluR2/3 (total: t34 = –0.009, p = 0.99; upper: t34 =
–0.576, p = 0.57; lower: t34 = 0.693, p = 0.49) or mGluR5 (t34 =
–0.106, p = 0.92).

A
1300

1200

1100

1000

900

800

700
CT

MDP

MDNP

Depression Collection

CT

MD

BD

SZ

Neuropathology Consortium

Diagnosis

B
Normalized mGluR5 binding density, fmol/mg

Analysis of demographic and clinical data
Mean pH, age at death, PMI and brain weight did not differ
among the MDNP, MDP and control groups (F = 0.054–
3.171, all p > 0.05). Excluding controls, further analyses revealed no significant differences between diagnoses (MDNP
v. MDP) for age of onset (t21 = –0.379, p = 0.71) or illness dur
ation (t21 = –0.417, p = 0.68). Individuals in the MDNP and
MDP groups were exposed to antipsychotic medication
(measured as fluphenazine equivalent units), although average estimated lifetime exposure did not differ significantly
between the groups (3 in the MDNP group v. 9 in the MDP
group, t10 = 0.940, p = 0.37). Quantitative antidepressant and
mood stabilizer medication histories were not available.

250

200

150

100

50

0
CT

MDP

MDNP

Depression Collection

CT

MD

BD

SZ

Neuropathology Consortium

Diagnosis

Fig. 2: Normalized (A) mGluR2/3 [3H]LY341495 and (B) mGluR5
[3H]MPEP binding density (as measured in fmol/mg tissue) in the
anterior cingulate cortex of control (CT; diamonds = Depression
Collection; solid circles = Neuropathology Consortium), major depression with psychosis (MDP; hollow circles), major depression
without psychosis (MDNP; Depression Collection = hollow squares;
Neuropathology Consortium = upward arrowheads), bipolar disorder (BD; downward arrowheads), and schizophrenia (SZ; solid
squares) groups. mGluR2/3 and mGluR5 binding densities were
not altered or differentially expressed in the anterior cingulate cortex in these neuropathologies.
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Neuropathology Consortium
Analysis of demographic and clinical data
Mean pH, age at death, PMI and brain weight did not differ
among the MDNP, BD, schizophrenia and control groups (F =
0.420–1.857, all p > 0.147). However, freezer storage time was
significantly greater in the BD group (281.73 d longer, p = 0.010)
and the schizophrenia group (282.86 d longer, p = 0.009) than
the control group. Excluding controls, further ANOVAs and
post hoc tests revealed significant differences between
diagnoses, with the MDNP group having a mean age at onset
that was 10.73 years older than the schizophrenia group (p =
0.016) and 12.46 years older than the BD group (p = 0.005). Illness duration also approached significance, being 8.63 years longer in the schizophrenia group than in the MDNP group (p =
0.08). Of the patients who had been exposed to antipsychotic
medication (12 in the BD group and 14 in the schizophrenia
group), lifetime antipsychotic exposure did not differ between
the groups (t24 = –1.557, p = 0.13). Quantitative antidepressant
and mood stabilizer medication histories were not available.
Diagnosis-related effects
One-way ANOVA revealed no significant diagnostic alterations in mGluR2/3 (overall: F3,56 = 1.387, p = 0.26; upper: F3,56 =
1.586, p = 0.20; lower: F3,56 = 0.847, p = 0.47) or mGluR5 (F3,56 =
0.541, p = 0.66) binding densities in the MDNP, BD and

schizophrenia groups compared with the control group
(Fig. 2). The ANCOVA controlling for age at death, brain pH,
brain weight, freezer storage time and PMI confirmed this
finding for both mGluR2/3 (total: F3,51 = 0.934, p = 0.43; upper:
F3,51 = 0.761, p = 0.52; lower: F3,51 = 0.818, p = 0.49 and mGluR5
(F3,51 = 1.010, p = 0.40). As age at disease onset, illness duration and lifetime fluphenazine equivalents were observed to
correlate with binding (Table 4 and Appendix, Table S1), we
performed additional ANCOVAs excluding control samples.
The data remained nonsignificant for both mGluR2/3 (total:
F2,35 = 0.998; p = 0.38; upper: F2,35 = 1.203; p = 0.31; lower: F2,35 =
0.497, p = 0.61) and mGluR5 (F2,35 = 0.382, p = 0.69), suggesting
no significant difference in mGluR2/3 and mGluR5 binding
among the MDNP, BD and schizophrenia groups.
Effects of demographic and clinical variables
Pearson correlations for mGluR2/3 and mGluR5 with con
tinuous variables (pH, age at death, PMI, freezer storage
time, brain weight, age at disease onset, duration of illness,
and lifetime fluphenazine equivalents) are presented in Table
4 and in the Appendix, Table S1. Various correlations for pH,
brain weight, PMI and freezer storage time were observed
across the diagnostic groups; these were accounted for by
ANCOVA and did not affect the diagnostic findings.
Consistent with our results in the Depression Collection,
age at death had a significant negative effect on mGluR2/3

Table 3: Pearson correlations for variables influencing mGluR2/3 and mGluR5 binding densities in
the anterior cingulate cortex within diagnostic groups of the Depression Collection
Diagnosis; variable

Age at death

Fluphenazine equivalent

All samples, n = 36
mGluR2/3 total

r = –0.551

p < 0.001

—

—

mGluR2/3 upper

r = –0.569

p < 0.001

—

—

mGluR2/3 lower

r = –0.403

p = 0.015

—

—

r = 0.359

p = 0.032

—

—

mGluR2/3 total

r = –0.551

p = 0.06

—

—

mGluR2/3 upper

r = –0.747

p = 0.005

—

—

mGluR2/3 lower

r = –0.134

p = 0.68

—

—

r = 0.023

p = 0.94

—

—

mGluR2/3 total

r = –0.570

p = 0.004

r = –0.289*

p = 0.19*

mGluR2/3 upper

r = –0.507

p = 0.011

r = –0.460*

p = 0.031*

mGluR2/3 lower

r = –0.529

p = 0.008

r = –0.047*

p = 0.84*

r = 0.545

p = 0.006

r = –0.005*

p = 0.98*

mGluR5 total
Controls, n = 12

mGluR5 total
Major Depression, all samples; n = 24

mGluR5 total

Major Depression, with psychosis; n = 11
mGluR2/3 total

r = –0.765

p = 0.006

—

—

mGluR2/3 upper

r = –0.748

p = 0.008

—

—

mGluR2/3 lower

r = –0.692

p = 0.018

—

—

r = 0.551

p = 0.08

—

—

mGluR5 total

Major Depression, without psychosis; n = 12
mGluR2/3 total

r = –0.371

p = 0.24

—

—

mGluR2/3 upper

r = –0.383

p = 0.22

—

—

mGluR2/3 lower

r = –0.335

p = 0.29

—

—

r = 0.587

p = 0.045

—

—

mGluR5 total
*n = 12.
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Discussion

binding in the control group (total: r = –0.695, p = 0.004; upper: r = –0.666, p = 0.007; lower: r = –0.575, p = 0.025) and in
the schizophrenia group (total: r = –0.528, p = 0.043; upper:
r = –0.458, p = 0.09; lower: r = –0.515, p = 0.049) groups, but
not in the MDNP or BD groups. Age at death displayed a
borderline significant correlation with mGluR5 in the schizophrenia group (r = 0.505, p = 0.06) but not in the MDNP, BD
or control groups. Illness duration also significantly and negatively correlated in the schizophrenia group for mGluR2/3
(total: r = –0.697, p = 0.004; upper: r = –0.734, p = 0.002; lower
r = –0.539, p = 0.038), although this correlation was not seen
with mGluR5. Although lifetime antipsychotic medication
did not differ between the schizophrenia and BD diagnostic
groups, a significant negative correlation with mGluR2/3
was observed, specifically in the BD group (Table 4).

The mGluR2/3 and mGluR5 receptors are targets of new
therapeutic approaches for psychiatric conditions, including
MD, BD and schizophrenia. Furthermore, animal studies
have suggested the involvement of these receptors in the
pathophysiologies of these disorders.1,11 In light of this, we
have examined binding to mGluR2/3 and mGluR5 in postmortem brains, specifically the ACC, of individuals with MD
(MDP, MDNP), BD and schizophrenia and compared them
to matched controls. In particular, we chose the receptor
binding technique and radioligands that target the same
binding sites as novel drugs currently under development to
determine how drugs targeting these receptor sites may be
affected in the patient. We report no significant diagnostic alterations of mGluR2/3 binding or mGluR5 binding in the
ACC in individuals with these pathologies.

Correlations with glutamatergic markers and signalling
partners in the SNCID
Explorative Spearman correlations with the data from the
present study and those from previous studies (available in
the SNCID) are presented in the Appendix, Table S2. Various
significant associations were observed, both overall and in individual pathologies, between mGluR2/3 and mGluR5 with
measures of NMDAR, AMPAR and kainate receptors as well
as signalling partners PSD95, PKC and BDNF.

Unaltered levels of mGluR2/3 and mGluR5 in depression
(with or without psychosis)
mGluR2/3 and mGluR5 are prominent prospective targets
in the treatment of mood disorders, as both clinical and preclinical studies have shown antidepressant properties of
antagonists or negative allosteric modulators targeted at

Table 4: Pearson correlations for variables influencing mGluR2/3 and mGluR5 binding
densities in the anterior cingulate cortex within diagnostic groups of the Neuropathology
Consortium.
Diagnosis; variable

Age at death

Fluphenazine equivalent

All samples, n = 60
mGluR2/3 total

r = –0.410

p = 0.001

—

—

mGluR2/3 upper

r = –0.464

p < 0.001

—

—

mGluR2/3 lower

r = –0.273

p = 0.035

—

—

r = 0.087

p = 0.51

—

—

mGluR2/3 total

r = –0.695

p = 0.004

—

—

mGluR2/3 upper

r = –0.666

p = 0.007

—

—

mGluR2/3 lower

r = –0.575

p = 0.025

—

—

mGluR5 total

r = –0.305

p = 0.27

—

—

mGluR2/3 total

r = –0.258

p = 0.35

—

—

mGluR2/3 upper

r = –0.355

p = 0.19

—

—

mGluR2/3 lower

r < 0.001

p = 0.10

—

—

r = –0.453

p = 0.09

—

—

mGluR2/3 total

r = –0.045

p = 0.87

r = –0.554

p = 0.032

mGluR2/3 upper

r = –0.286

p = 0.30

r = –0.525

p = 0.045

mGluR2/3 lower

r = 0.170

p = 0.55

r = –0.482

p = 0.07

mGluR5 total

r = 0.023

p = 0.93

r = –0.131

p = 0.64

mGluR2/3 total

r = –0.528

p = 0.043

r = –0.109

p = 0.70

mGluR2/3 upper

r = –0.458

p = 0.09

r = 0.016

p = 0.96

mGluR2/3 lower

r = –0.515

p = 0.049

r = –0.225

p = 0.42

r = 0.505

p = 0.06

r = 0.477

p = 0.07

mGluR5 total
Controls, n = 15

Major depression, n = 15

mGluR5 total
Bipolar disorder, n = 15

Schizophrenia, n = 15

mGluR5 total
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mGluR2/3 and mGluR5.1,12 To our knowledge, we are the
first to report that neither mGluR2/3 nor mGluR5 binding
levels are altered in the ACC of individuals with MD, in the
presence (MDP) or absence (MDNP) of psychosis. Our results are in line with a previous study reporting unaltered
mGluR2 and mGluR3 gene expression in the postmortem
ACC of individuals with MD.9 We found no other studies
that have investigated mGluRs in the ACC in individuals
with depression. In other brain regions of depressed patients, an increase in mGluR2/324 and reduction of mGluR5
protein in the prefrontal cortex (BA10) have been reported,
together with reduced (in vivo) prefrontal cortical mGluR5
binding25 and increased mGluR5 gene expression in the locus coeruleus.26 Although it is difficult to draw conclusions
from only a small number of studies, the inconsistencies between these findings highlight the inherent regional differences in mGluRs in the pathophysiology of MD as well as
the importance of considering psychiatric subclass. These
prior studies have an important limitation in that they do
not distinguish between MDP and MDNP, particularly
since differential proteome profiles have been recently reported, specifically between MDNP and MDP.17

mGluR2/3 and mGluR5 binding does not differ in BD and
schizophrenia compared with depression
In line with depression with and without psychosis we report
that mGluR2/3 and mGluR5 binding density are unaltered in
the ACC in individuals with schizophrenia and BD. While
mGluR binding, to our knowledge, has not previously been
measured in individuals with BD, studies in the prefrontal
cortex, thalamus and striatum of individuals with schizophrenia have likewise reported no change in mGluR2/319,27–30
or mGluR511,21 (binding, protein or mRNA). Our findings
highlight that in the ACC there are no distinct differences between the overlapping diagnoses of MDNP, MDP, schizophrenia and BD with regards to binding to mGluR2/3 and
mGluR5. This suggests that novel pharmacological modulators of mGluR2/3 and mGluR5 may have unhindered binding sites in all these disorders.
It should, however, be noted that there may be wider dysregulations in mGluR2/3 and mGluR5 function that were not
measured within the scope of our study or that there may be
alterations in other mGluR subtypes dependent on specific
brain regions.12 For example, Volk and colleagues31 found reductions in mGluR1a mRNA, but not mGluR5, in the prefrontal cortex (BA9 and BA42) of patients with schizophrenia.
Conversely another more recent study found mGluR5
mRNA and protein to be reduced specifically in BA9 and the
lateral cerebellum in individuals with schizophrenia.32 These
examples highlight the heterogeneity and intricacies of spectrum disorders such as schizophrenia.33

Current and novel pharmacotherapy implications
In the present study we found evidence of a negative association between mGluR2/3 binding and antipsychotic dose,
specifically in individuals with BD and MD, but not in those
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with schizophrenia. Previous postmortem studies have reported no association between antipsychotic dose and
mGluR2/319,27,28 or mGluR5,21 specifically in patients with
schizophrenia. Animal studies have reported no effect of anti
psychotics on mGluR2/334 or mGluR5 binding.21 The effects of
antidepressants have not been as well studied, and while reliable quantitative lifetime antidepressant drug history was not
available in the present study, our previous work found no association of antidepressant history and mGluR5 binding and
protein in the DLPFC in individuals with schizophrenia.21
Deschwanden and colleagues,25 however, found that anti
depressant treatment may reduce mGluR5 binding specifically
in the precentral gyrus of antemortem patients with MD. Animal studies have shown that tricyclic antidepressant treatment
significantly increases mGluR2/335 and mGluR5a36 protein in
the rat hippocampus, although another study found that total
mGluR5 protein levels were unaltered.35 To our knowledge,
there are no prior studies on antidepressant effects specifically
in the ACC to shed light on these findings; therefore, further
investigation is required.
The mGluR-targeted modulators have shown promising
antipsychotic and antidepressant therapeutic potential in preclinical and clinical studies. Orthosteric and allosteric modulators of mGluRs target binding sites on either the N-terminus
(mGluR2/3) or transmembrane (mGluR5) domain, respect
ively.1,11,13,37 These orthosteric and allosteric binding sites
were the same targets of the radioligands used in the present
study. As we report that these binding sites are not altered in
the ACC in psychopathology, mGluR2/3 and mGluR5 may
be unimpeded targets for novel antidepressant and antipsychotic intervention. As results from recent clinical trials with
mGluR modulators indicated that specific single nucleotide
polymorphisms (SNPs) were associated with treatment response,38 further study into these same binding sites in individuals with these SNPs would be of value. In addition, we
consistently found a negative correlation between mGluR2/3
binding and age in the control, schizophrenia and MDP
groups, with no association in the MDNP and BD groups.
Age-related differences in treatment approaches remain an
issue,39 and our findings suggest there may be differential
treatment responses to these novel therapeutics depending
on the pathology and age of the patient.

Association of mGluRs with markers in the wider
glutamatergic system
In addition to the metabotropic group of glutamate receptors,
glutamate signalling is also transduced through the ionotropic
glutamate receptors NMDAR, AMPAR and kainate receptors.
The NMDAR and AMPAR receptors are of particular interest as
they signal closely with mGluR511 and mGluR2/3,12 respect
ively, and novel mGluR2/3- and 5- based drugs are proposed to
exert their therapeutic effects, at least partially, through their influence on NMDAR and AMPAR.11,12 In addition, PSD-95 is a
key signalling partner of mGluR5 as it physically and functionally links it to NMDAR in the postsynapse, while PKC and
BDNF are downstream signalling effectors of mGluR5/
NMDAR signalling.11 We explored the association of mGluR2/3
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and mGluR5 measured in the present study in relation to meas
ures of these glutamatergic markers as available on the SNCID.
We chose a total of 29 markers representing glutamatergic
markers and signalling partners within the cingulate cortex.
As expected, we observed a number of differential associations between mGluR2/3, mGluR5 and these glutamatergic markers and signalling partners (see the Appendix,
Table S2). Many of these associations were specific to 1 of
the 3 psychiatric disorders examined, indicating that there
may be differential associations in the pathophysiologies of
these disorders. However, although correlation analyses are
useful to identify associations between markers, they do not
indicate causality and must be treated as exploratory. These
associations may provide direction for future studies aiming to distinguish pathological differences between these
psychiatric disorders.

Limitations
While our findings suggest possible age-related differences
between the psychotic and mood components, further analysis in a larger postmortem cohort is required to support this
notion. In addition, further studies are required to determine
if mGluR2/3 or mGluR5 function or downstream signalling
are altered in these pathologies. It should be noted that despite no pathological alteration of mGluR2/3 and mGluR5
binding sites in the present study, the ACC remains highly
involved in these pathologies as alterations of various neuro
transmitters and their associated receptors have been
reported in this brain region.3,7,40–42 Although our study provides valuable information on these binding sites in psychi
atric pathology, additional studies examining binding specif
ically to membranous mGluR2/3 and mGluR5 and the
affinity of novel mGluR2/3- and mGluR5-targeting drugs for
these receptors in psychiatric disorders will provide valuable
insight into the effectiveness of these drugs in the patient.33
One confound of postmortem studies in neuropsychiatric
disorders, is the presence of comorbid substance abuse, especially alcohol and drug abuse, or at least substantially higher
alcohol43 and illicit drug44 intake in patients with psychiatric
disorders. While reliable quantitative patient histories were
not available in the present study, mGluR1/5 densities in the
prefrontal cortex may be affected by alcohol,45 and mGluR2
gene expression was reported to be reduced in the ACC of patients with alcohol addiction.46 Furthermore, there is a growing
body of evidence suggesting that mGluRs may be involved in
drug and alcohol addiction disorders.47 Therefore, the molecular effects of alcohol and drug use should be considered when
interpreting the present and prior/future studies.

terations in mGluR2/3 or mGluR5 binding compared with
controls or between any studied pathological state. This suggests that mGluR2/3- and mGluR5-based therapeutics used to
treat emotional and cognitive deficits may have unhindered
binding capacity in these pathological states. Future studies
may extend on this work by investigating mGluR protein/
mRNA expression and their association with other mGluRs,
specifically in the ACC and other brain limbic structures; this
would increase our understanding of the role of mGluRs in the
neuropathologies of psychiatric disease and elucidate their
treatment potential.
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